Share on LinkedInShare on LinkedIn

ARTICLE · 31 JANUARY 2023

Exports Under The Bolar Exception: A Key Arrow In The Indian Generics Quiver

India is the largest producer of generic drugs in the world, and thus, it is no surprise that a great deal of patent litigation in India has centred on the manufacture of generics.

IndiaIntellectual Property

India is the largest producer of generic drugs in the world, and thus, it is no surprise that a great deal of patent litigation in India has centred on the manufacture of generics. While there are provisions in the law that permit the use of patented drugs for research and development ("R&D") and for obtaining regulatory approvals, permissibility around the export of such drugs for similar purposes can be in the grey. This is because the purpose of export may be difficult to clearly establish. This note attempts to examine the latest position on this issue, while discussing the ambit of related exceptions to patent infringement.

Introduction

A patentee has the right to stop others from making, using, selling, and distributing the patented invention in a defined jurisdiction for a specific period of time. However, many jurisdictions also recognise that this right is not absolute, and there may be acts relating to a patent that do not always constitute patent

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from